Allergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved by the FDA in December, but is still facing a challenge in the market.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,